Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Temozolomide or BCNU in Recurrent Glioblastoma
NCT00086879Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of erlotinib in glioblastoma multiforme (GBM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival at 6 months. Started May 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00086879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086879.